Companies
/Healthcare
Revvity Inc
$152.64
▼ $2.07 (−1.34%) today
Markets closed · 8:42pm ET
24/7 Wall St. View
RVTY at a Glance
Valuation
- Market cap
- $17.0B
- P/E ratio
- 73.0
- Dividend yield
- 0.18%
Profitability
- Revenue (TTM)
- $2.9B
- Profit margin
- 8.2%
- EPS (TTM)
- $2.09
Price
- 52-week range
- $81 – $166
- 24/7 target
- $172.94
- Street target
- $147.53
Earnings
- Next report
- Nov 3, 2026
Headquartered in Waltham, MA Fiscal year ends December NYSE: RVTY revvity.com
About Revvity
Revvity, Inc. (NYSE: RVTY) provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development and diagnosis to cure. The company operates through two reporting segments: Life Sciences, which serves pharmaceutical, biotech, and academic customers with translational multi-omics technologies, biomarker identification, imaging, and informatics solutions; and Diagnostics, which provides screening, detection, and diagnostic capabilities to diagnostic labs, healthcare providers, and governments. With 2025 revenue of approximately $2.9 billion and approximately 11,000 employees, Revvity is a member of the S&P 500 index and serves customers in more than 160 countries. The company recently entered into a definitive agreement to divest its Immunodiagnostics business in China. Updated
Frequently Asked Questions
What does Revvity do?
Revvity, Inc. (NYSE: RVTY) provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development and diagnosis to cure.
What is the RVTY stock price target?
24/7 Wall St.'s 12-month price target for RVTY is $172.94, rated Buy. The Wall Street consensus target is $147.53. RVTY price prediction →